IPO Year: 2014
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/27/2024 | $65.00 | Outperform | BMO Capital Markets |
6/11/2024 | $54.00 | Outperform | Robert W. Baird |
4/29/2024 | $46.00 | Outperform | Leerink Partners |
3/21/2024 | $61.00 | Outperform | William Blair |
BMO Capital Markets initiated coverage of Neurogene with a rating of Outperform and set a new price target of $65.00
Robert W. Baird initiated coverage of Neurogene with a rating of Outperform and set a new price target of $54.00
Leerink Partners initiated coverage of Neurogene with a rating of Outperform and set a new price target of $46.00
William Blair initiated coverage of Neurogene with a rating of Outperform and set a new price target of $61.00
SC 13G - Neurogene Inc. (0001404644) (Subject)
Expanded Phase 1/2 gene therapy trial for Rett syndrome to inform future registrational study design; Company remains on track to share interim clinical data in 4Q:24 Strong financial position with runway into 2H:26 following reverse merger and private financing in December 2023 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2023 financial results and highlighted recent corporate updates. "We started the year with strong execution in our Phase 1/2 NGN-401 gene therapy trial for female pediatric patients with Rett syndrom
4 - Neurogene Inc. (0001404644) (Issuer)
4 - Neurogene Inc. (0001404644) (Issuer)
4 - Neurogene Inc. (0001404644) (Issuer)
4 - Neurogene Inc. (0001404644) (Issuer)
4 - Neurogene Inc. (0001404644) (Issuer)
4 - Neurogene Inc. (0001404644) (Issuer)
4 - Neurogene Inc. (0001404644) (Issuer)
4 - Neurogene Inc. (0001404644) (Issuer)
10-Q - Neurogene Inc. (0001404644) (Filer)
8-K - Neurogene Inc. (0001404644) (Filer)
8-K - Neurogene Inc. (0001404644) (Filer)
8-K - Neurogene Inc. (0001404644) (Filer)
8-K - Neurogene Inc. (0001404644) (Filer)
8-K - Neurogene Inc. (0001404644) (Filer)
8-K - Neurogene Inc. (0001404644) (Filer)
10-Q - Neurogene Inc. (0001404644) (Filer)
8-K - Neurogene Inc. (0001404644) (Filer)
8-K - Neurogene Inc. (0001404644) (Filer)
NGN-401 gene therapy for Rett syndrome received RMAT designation from FDA based on preliminary clinical evidence indicating the potential to address unmet medical needs NGN-401 selected for FDA START Program, also designed to accelerate development Interim NGN-401 efficacy data from Cohort 1 remains on track for 4Q:24 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2024 financial results and highlighted recent corporate updates. "We are pleased that NGN-401 gene therapy for Rett syndrome received RMAT designation, in addition to the
Designation based on preliminary clinical evidence from ongoing NGN-401 clinical trial that shows potential to address unmet medical needs in Rett syndrome RMAT designation provides an opportunity for an Accelerated Approval pathway under the 21st Century Cures Act, and is in addition to NGN-401's selection by the FDA for the START Pilot Program Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that NGN-401 received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the treatment of Rett syndrom
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the BMO 2024 Genetic Medicines Summit. Format: Management will participate in the panel, "Gene Therapy in Rare Disease: Unmet Need + Lack of Alternatives = Commercial Viability?" and participate in investor meetings Date: Tuesday, July 9 at 8:30 a.m. ET About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and t
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Neurogene will be added to the Russell 3000® Index, effective at the open of U.S. equity markets today, Monday, July 1, 2024. The annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30, 2024, ranking them by total market capitalization. Neurogene's membership in the U.S. all-cap Russell 3000® Index will remain in place for one year. Neurogene has also been added to the Russell 2000® Index and the Russell Microcap® Index. "We are proud of all that we have
High-dose NGN-401 has been well-tolerated, and low-dose NGN-401 continues to show a favorable safety profile Interim safety data presented at the International Rett Syndrome Foundation (IRSF) ASCEND Summit Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first patient in Cohort 2 received high-dose NGN-401 gene therapy in the Phase 1/2 trial for female pediatric patients with Rett syndrome, and high-dose NGN-401 has been well-tolerated following dosing in May 2024. The Company also provided an update on interim safety data on the first three p
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences: Goldman Sachs 45th Annual Global Healthcare Conference Format: Management will present a corporate overview and participate in investor meetings Date: Wednesday, June 12 at 1:20 p.m. ET 2024 IRSF (International Rett Syndrome Foundation) Rett Syndrome Scientific Meeting Format: Management and Bernhard Suter, M.D., Medical Director of the Blue Bird Circle Rett Center at Texas Children's Hospital, Associate Professor of Pediatrics and Neu
NGN-401 is one of only three CBER programs chosen by FDA NGN-401 was selected based on potential for clinical benefits and clinical development program readiness START Program provides sponsors enhanced communications with FDA to accelerate development of rare disease therapies Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that its NGN-401 gene therapy for Rett syndrome has been selected to participate in the U.S. Food and Drug Administration (FDA) Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program. As part of the
Presented favorable safety data from Phase 1/2 NGN-401 gene therapy trial for Rett syndrome at ASGCT Annual Meeting Received Australian HREC approval for NGN-401 trial Remains on track to provide interim NGN-401 efficacy data from Cohort 1 in 4Q:24 Strong balance sheet with cash runway into 2H:26 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2024 financial results and highlighted recent corporate updates. "We have made substantial progress in our NGN-401 Rett syndrome gene therapy program since the beginning of the year, including
NGN-401 has been generally well-tolerated by first three patients dosed, with three to nine months of follow-up No signs or symptoms of overexpression toxicity, including in one patient with a mild variant predicted to result in residual MeCP2 expression Neurogene remains on track to provide interim efficacy data from the trial in 4Q:24 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome, which showed that NGN-401 was generally well-tolerated by
NGN-401 has been generally well-tolerated by three patients with multiple months of follow-up Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be presented at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting. The data show that the NGN-401 gene therapy candidate has been generally well-tolerated, and there have been no treatment-emergent or procedure-related serious adverse events or signs of MeCP2 overexpression-rel
BMO Capital analyst Keith Tapper initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price Target of $65.
Gainers Tempest Therapeutics (NASDAQ:TPST) shares rose 32.8% to $3.79 during Thursday's pre-market session. The company's market cap stands at $84.0 million. Neurogene (NASDAQ:NGNE) shares rose 31.92% to $40.0. The company's market cap stands at $519.2 million. Geovax Labs (NASDAQ:GOVX) shares rose 28.94% to $2.45. The company's market cap stands at $6.1 million. SAB Biotherapeutics (NASDAQ:SABS) stock moved upwards by 24.03% to $3.2. The market value of their outstanding shares is at $29.5 million. Trevena (NASDAQ:TRVN) stock rose 23.33% to $0.44. The market value of their outstanding shares is at $8.0 million. Molecular Partners (NASDAQ:MOLN) stock rose 22.23% to $9.73. The company's
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $51 price target.
Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday's session after the company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates. Quantum shares dipped 44.5% to $0.43 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Reliance Global Group, Inc. (NASDAQ:RELI) shares jumped 350% to $1.00 after the company issued an update on the pending acquisition of Spetner Associates. NLS Pharmaceutics AG (NASDAQ:NLSP) shares rose 166% to $0.3930 after jumping 30% on Monday. Actelis Networks, Inc. (NASDAQ:ASNS) climbed 80.9% to $2.08 after the company announced a partnership with Carahsoft Tech
High-dose NGN-401 has been well-tolerated, and low-dose NGN-401 continues to show a favorable safety profileInterim safety data presented at the International Rett Syndrome Foundation (IRSF) ASCEND SummitNeurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first patient in Cohort 2 received high-dose NGN-401 gene therapy in the Phase 1/2 trial for female pediatric patients with Rett syndrome, and high-dose NGN-401 has been well-tolerated following dosing in May 2024. The Company also provided an update on interim safety data on the first three patients
Baird analyst Joel Beatty initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price Target of $54.
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $51 price target.